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The present study has examined the antidiabetic effects of 21 days co-administration of xenin-8-Gln with the dual-acting fusion peptide, exendin-4/gastrin, as well as persistence of beneficial metabolic benefits, in high fat fed (HFF) mice. Xenin-8-Gln, exendin-4 and gastrin represent compounds that activate receptors of the gut-derived hormones, xenin, glucagon-like peptide-1 (GLP-1) and gastrin, respectively. Twice-daily administration of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides significantly reduced circulating glucose, HbA1c and cumulative energy intake. Combination therapy with xenin-8-Gln and exendin-4/gastrin increased circulating insulin. All HFF mice treated with exendin-4/gastrin presented with body weight similar to lean control mice on day 21. Each treatment improved glucose tolerance and the glucose-lowering actions of glucose dependent insulinotropic polypeptide (GIP), as well as augmenting glucose- and GIP-induced insulin secretion, with benefits being most prominent in the combination group. Administration of exendin-4/gastrin alone, and in combination with xenin-8-Gln, increased pancreatic insulin content and improved the insulin sensitivity index. Pancreatic beta-cell area was significantly increased, and alpha cell area decreased, by all treatments, with the combination group also displaying enhanced overall islet area. Notably, metabolic benefits were generally retained in all groups of HFF mice, and especially in the combination group, following discontinuation of the treatment regimens for 21 days. This was associated with maintenance of increased islet and beta-cell areas. Together, these data confirm the antidiabetic effects of co-activation of GLP-1, gastrin and xenin cell signalling pathways, and highlight the sustainable benefits this type of treatment paradigm can offer in T2DM.
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1.	Introduction
The increasing worldwide prevalence of type 2 diabetes mellitus (T2DM), and related complications, demands for the development of more effective, and safe, treatment options (Zimmet et al. 2016). In this regard, certain types of bariatric surgeries are known to provide rapid remission from T2DM, deemed to be linked to alterations in the secretion and action of gastrointestinal (GIT) derived hormones (Meek et al. 2016). Since surgery is clearly not the answer for the T2DM epidemic, replicating the GIT hormonal environment following these surgeries represents a realistic alternative therapeutic approach. 
A number of studies have highlighted the metabolic benefits of concurrent activation of various GIT hormone receptors in T2DM, as opposed to activation of a single receptor target (Gault et al. 2011; Bhat et al. 2013b; Irwin et al. 2013), akin to the impact of bariatric surgery. Many of these investigations have adopted the approach of using single hybrid peptides engineered to co-activate two or more receptors, with glucagon-like peptide-1 (GLP-1) structures central to the hybrid design (Bhat et al. 2013a; Gault et al. 2013; Irwin et al. 2015). Indeed, the approach is typified by LY3298176, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with notable benefits in T2DM patients (Frias et al. 2018; Coskun et al. 2018). However, insensitivity to the biological actions of GIP is a widely recognised phenomenon in T2DM (Nauck et al. 1993). Thus, approaches that can restore GIP effectiveness in T2DM could yield even more beneficial effects in the T2DM clinic. In this regard, it has recently been shown that xenin, a GIT peptide hormone co-secreted postprandially with GIP (Feurle et al. 1992), potentiates the biological actions of GIP in rodents (Martin et al. 2012; Gault et al. 2015) and humans (Wice et al. 2012). Therefore, hybrid peptides that incorporate a xenin element could have particularly powerful antidiabetic effects. 
In line with this, our laboratory has synthesised and characterised a number of xenin-based hybrid peptides, with benefits in preclinical models of T2DM (Hasib et al. 2017, 2018a,b, 2019). More notably, we have fully characterised a triple-acting GLP-1/gastrin/xenin fusion peptide, namely exendin-4/gastrin/xenin-8-Gln (Hasib et al. 2018b). To create a potentially more attractive compound, the biological half-life of exendin-4/gastrin/xenin-8-Gln was extended through acylation, to generate exendin-4(Lys27PAL)/gastrin/xenin-8-Gln (Hasib et al. 2019). Whilst exendin-4(Lys27PAL)/gastrin/xenin-8-Gln displayed noteworthy antidiabetic actions following prolonged injection in obese-diabetic (ob/ob) mice, benefits over exendin-4/gastrin/xenin-8-Gln were not entirely obvious (Hasib et al. 2019). Accordingly, it appears that duration of biological action was not the sole reason behind the somewhat indifferent antidiabetic efficacy of exendin-4/gastrin/xenin-8-Gln (Hasib et al. 2018b). In this regard, the main benefit of gastrin in diabetes is thought to be linked to beta-cell regeneration (Rooman et al. 2002). Although the C-terminal amide group of gastrin is not entirely necessary for biological activity, especially in relation to growth factor actions (Seva et al. 1994; Hollande et al. 1997), there is a suggestion that C-terminal amidation improves overall bioactivity of gastrin (Morley et al. 1965). Thus, the gastrin entity within exendin-4/gastrin/xenin-8-Gln was unable to be amidated due to the structure of the hybrid peptide. 





Peptides were procured from EZBiolab Inc (Parsippany, NJ, USA).  Peptide purity and identity were confirmed using an in-house RP-HPLC and MALDI-TOF MS as detailed previously (Martin et al. 2013).

2.2 Animals
Studies were conducted in 8-10 weeks old male NIH Swiss mice (Envigo Ltd, UK). Prior to commencement of experiments, mice were given free access to high fat diet (45% fat, 20% protein, and 35% carbohydrate, Special Diet Services, Essex, U.K.) for 3 weeks and then received three separate low dose streptozotocin (STZ) injections (4 h fast, 50 mg/kg bw, i.p., in sodium citrate buffer, pH 4.5, Sigma-Aldrich, UK) at one week intervals over an additional 3 week period, as described previously (Millar et al. 2016). At week 6, animals exhibited progressive hyperglycaemia (18.7±1.3 vs. 7.1±0.3 mmol/l; P<0.001), body weight gain (39.9±1.1 vs. 32.3±0.6 g; P<0.001) and hyperinsulinaemia (2.1±0.5 vs. 0.8±0.1 ng/ml; P<0.05) compared with age-matched control mice maintained on normal laboratory chow (10% fat, 30% protein and 60% carbohydrate, Trouw Nutrition, UK). All animals were housed individually in an air-conditioned room (22 ± 2 °C) with 12 h light and 12 h dark cycle and had free access to drinking water. All experiments were conducted according to U.K. Animals (Scientific Procedures) Act 1986. No animals died as a result of the experimental interventions, and all mice were humanely culled in days 29 or 50, as depicted in the experimental scheme.

2.3 Experimental design
Following the 6 week period of diabetes induction, drug treatments were commenced as follows: Group 1 (saline control, n=12; 0.9% NaCl, w/v; i.p.); Group 2 (exendin-4/gastrin, n=12; 25 nmol/kg bw; i.p.); Group 3 (xenin-8-Gln, n=12; 25 nmol/kg bw; i.p.); Group 4 (exendin-4/gastrin in combination with xenin-8-Gln, n=12; each at 25 nmol/kg bw; i.p.). All treatments were administered twice daily (09:30 and 17:00 h) for 21 days and mice remained on respective diets for the duration of the study. Separate studies (Leckstorm et al. 2009; Cooke et al. 2009; Dossat et al. 2011; Richard et al. 2015), as well as our own independent unpublished observations using kaolin intake (pica) assay in rats, support the notion that malaise or taste aversion did not contribute to changes observed with the dosing regimen in the present study. In addition, there were no obvious adverse behaviours such as increased resting, hunched posture or tremors observed following administration of any of the treatments. Cumulative food intake, body weight, non-fasting glucose and insulin concentrations were monitored at 3-4 day intervals. Groups of 12 mice were treated for 21 days, with sub-groups (n=6) of mice then randomly selected to progress to either metabolic profiling as detailed below, or observations on food intake, body weight, glucose and insulin continued in the remaining mice (n=6) until day 42. Thus, the first animal cohort had n=12 mice from day -3 until day 21, and then n=6 from day 21 onwards for metabolic tests conducted on days 21, 24 and 27. The second cohort of mice had n=6 throughout and were used to test metabolic parameters (days 42, 45 and 48) after discontinuation of daily peptide treatment at day 21 (see experimental scheme). Measurement of food intake, body weight, non-fasting glucose and insulin was terminated in the first cohort of animals on day 21, and in the second cohort of animals on day 42 (see experimental scheme), with animals culled on day 29 or 50, as appropriate. Circulating plasma glucagon levels and % HbA1c were measured at the end of the treatment periods. In addition, i.p. glucose tolerance (18 mmol/kg bw), biological response to GIP (18 mmol/kg glucose plus GIP (25 nmol/kg); i.p.) and insulin sensitivity (20 U/kg bw; i.p.) tests were performed at the end of each study. All food and water was withdrawn from the animals for the duration of the metabolic tests, as depicted in Figs. 2-4. These tests were performed in the timeline as detailed in the experimental scheme, with daily treatment regimens continued during metabolic test period. The insulin sensitivity index, fasting glucose (mmol/L) x fasting insulin (mU/L), a marker of insulin resistance was also calculated in 18 h fasted mice. For terminal investigations, animals were killed by lethal inhalation of CO2 followed by cervical dislocation. Analysis included measurement of percentage body fat by DEXA scanning (PIXImus densitometer, Inside Outside Sales, Wisconsin, USA) and determination of pancreatic insulin content. In addition, pancreatic histological analyses were conducted in a blinded manner as previously described from our laboratory (Hasib et al. 2017), using mouse anti-insulin (1:500; Abcam, ab6995) and guinea-pig anti-glucagon (PCA2/4, 1:400; raised in-house) primary antibodies alongside Alexa Fluor 594 goat anti-mouse IgG (1:400) and Alexa Fluor 488 goat anti-guinea pig IgG (1:400) secondary antibodies (both Abcam). Slides were viewed under a FITC (488 nm) or TRITC filter (594 nm) using a fluorescent microscope (Olympus system microscope, model BX51) and photographed using a DP70 camera adapter system. Islet parameters were analysed using CellF image analysis software (Olympus Soft Imaging Solutions, GmbH). 

2.4 Biochemical analysis 
Blood samples were collected and processed as described previously (Hasib et al. 2017). Plasma and pancreatic insulin were assayed by a modified dextran-coated charcoal radioimmunoassay (Flatt and Bailey, 1981). Plasma glucagon and HbA1c were measured using commercially available ELISA (EZGLU-30K, Merck Millipore, Germany), and A1cNow+ kits (PTS diagnostics, IN, USA), respectively. 

2.5 Statistical analysis 




3.1 Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on body weight, cumulative energy intake, non-fasting glucose and insulin in HFF mice 
Twice daily treatment with exendin-4/gastrin, xenin-8-Gln or a combination of both peptides for 21 days resulted in progressive decline in body weight in HFF mice, but this failed to reach significance compared to saline HFF controls (Fig. 1A). However, body weights of mice treated with exendin-4/gastrin alone, or in combination with xenin-8-Gln, were not significantly different from lean controls by day 21 (Fig. 1A).  Following cessation of treatment for 21 days, body weights of saline control HFF mice were still significantly (P<0.01) elevated when compared to lean controls, but there were no differences in body weights between all groups of HFF mice (Fig. 1A). Treatment with exendin-4/gastrin alone, or in combination with xenin-8-Gln, for 21 days significantly reduced (P<0.05 to P<0.01) percentage body fat when compared to saline HFF controls (Fig. 1B). However, beneficial effects on body fat content did not persist 21-days after cessation of treatment (Fig. 1B). The same treatment modalities induced significant reductions (P<0.05 to P<0.001) in cumulative food intake from day 7 onwards, with xenin-8-Gln alone also reducing (P<0.01 to P<0.001) energy intake from day 18 onwards (Fig. 1C). Discontinuation of treatment for 21 days revealed persistent appetite suppressive effects (P<0.05 to P<0.001) in all peptide treated groups, but this effect was eventually lost by day 42 in xenin-8-Gln treated mice (Fig. 1C). 
All treatments significantly (P<0.001) reduced non-fasting blood glucose levels by day 21 (Fig. 1D). Glucose levels of HFF mice treated with exendin-4/gastrin alone or in combination with xenin-8-Gln were indistinguishable from lean controls from day 4 onwards (Fig. 1D). Interestingly, following cessation of treatment, glucose levels were still significantly lower (P<0.05 to P<0.001) in HFF mice previously treated with xenin-8-Gln alone or in combination with exendin-4/gastrin on day 42 when compared to saline controls (Fig. 1D). Moreover, glucose levels in the combined treatment HFF group were not significantly different from lean controls at the end of the study (Fig. 1D). All treatments significantly elevated (P<0.05 to P<0.001) plasma insulin concentrations at various observations points during the 21-day treatment regimen when compared to lean controls (Fig. 1E). Combination therapy induced elevated (P<0.05) circulating insulin when compared to HFF controls on day 21 (Fig. 1E).  A trend for increased plasma insulin concentrations in all treated HFF mice was evident throughout the 21-day treatment cessation period, especially in HHF mice previously treated with exendin-4/gastrin alone and in combination with xenin-8-Gln (Fig. 1E).  
 
3.2 Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on glucose tolerance and insulin secretion in HFF mice 
Twice daily administration of exendin-4/gastrin alone or in combination with xenin-8-Gln significantly reduced (P<0.05 to P<0.001) individual glucose values at 15, 30, 60 and 105 min time points post glucose injection, culminating in marked reductions (P<0.001) in overall glucose AUC values when compared to saline HFF controls (Fig. 2A). Indeed, these groups of HFF had similar glucose levels as lean control mice during the glucose challenge (Fig. 2A). Xenin-8-Gln treated HFF mice also had decreased (P<0.001) glucose levels at 105 min post glucose injection, as well as reduced (P<0.05) AUC values (Fig. 2A). Consistent with improved glucose handling, overall AUC glucose-induced insulinotropic responses were significantly (P<0.05 to P<0.01) elevated in all treated HFF mice compared to lean control mice, and when compared to saline treated HFF mice in the combined treatment group (Fig. 2B). Following cessation of treatment, the overall glycaemic excursion was reduced (P<0.05), and associated with an elevated (P<0.05) overall insulin secretory response, in HFF mice previously treated with a combination of exendin-4/gastrin and xenin-8-Gln, when compared to saline treated HFF controls (Fig. 2C,D). However, the overall glycaemic and insulin secretory responses were elevated (P<0.05 to P<0.01) in all HFF treatment groups when compared to lean controls at the end of the study (Fig. 2C,D). 

3.3 Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on metabolic response to GIP in HFF mice 
Twice daily treatment with xenin-8-Gln alone, or in combination with exendin-4/gastrin, significantly improved (P<0.05 to P<0.001) the overall glucose lowering and insulinotropic action of GIP when compared to HFF saline controls (Fig. 3A,B). The combined treatment approach significantly (P<0.05 to P<0.001) augmented GIP-induced insulin secretion to a greater extent than in any other treatment (Fig. 3B). In terms of glucose-lowering actions, all HFF mice treated with xenin-8-Gln had a similar glycaemic excursion as lean control mice, and significantly (P<0.001) reduced when compared to saline HFF controls (Fig. 3A). At the end of the intervention period, HFF mice previously treated with exendin-4/gastrin in combination with xenin-8-Gln exhibited a significantly reduced (P<0.01) overall glycaemic excursion compared to HFF controls, but this was elevated (P<0.01) when compared to lean controls (Fig. 3C). The other treatment modalities, namely exendin-4gastrin or xenin-8-Gln alone, had no impact on GIP-induced reductions of blood glucose (Fig. 3C). Previous administration of all treatments, augmented (P<0.01) overall GIP-induced insulin secretion at the end of the study when compared to lean control mice (Fig. 4C,D). 

3.4 Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on insulin sensitivity in HFF mice 
As expected, exogenous insulin administration induced clear hypoglycaemic effects in both lean control and HFF mice (Fig. 4A,B,D,E). There was no obvious impact of either high fat feeding or treatment interventions on the glucose lowering action of insulin (Fig. 4A,B) or 42 (Fig. 4C,D). However, the insulin sensitivity index was significantly (P<0.05 – P<0.01) improved in all HFF treatment groups, as well as following cessation of treatment, when compared to HFF saline controls, but impaired (P<0.05 – P<0.001) compared to lean controls (Fig. 4C,F). Fasting values for glucose and insulin on days 29 and 50 for lean control, saline control, exendin-4/gastrin, xenin-8-Gln and the combination treatment group were 3.8 ± 0.3 and 4.6 ± 0.4 mmol/l, 0.3 ± 0.1 and 0.3 ± 0.1 ng/ml; 12.1 ± 2.0 and 11.6 ± 1.8 mmol/l, 0.4 ± 0.1 and 0.4 ± 0.1 ng/ml; 6.8 ± 0.4 and 6.3 ± 0.8 mmol/l, 0.4 ± 0.1 and 0.4 ± 0.1 ng/ml; 8.2 ± 1.0 and 6.3 ± 0.9 mmol/l, 0.3 ± 0.1 and 0.4 ± 0.1 ng/ml and 7.5 ± 0.6 and 6.0 ± 0.8 mmol/l, 0.3 ± 0.1 and 0.5 ± 0.1 ng/ml, respectively. There were no statistical differences in fasting plasma insulin concentrations, but fasting glucose was significantly (P < 0.05 – P < 0.01) lower in all treated groups compared to saline controls on either days 29 or 50.

3.5 Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on pancreatic insulin content, plasma glucagon and %HbA1c in HFF mice 
Pancreatic insulin content was elevated (P<0.05) in HFF mice treated with exendin-4/gastrin alone or in combination with xenin-8-Gln when compared to saline control HFF mice, and in the same groups of mice following cessation of all treatments (Fig. 5A,D). Plasma glucagon levels were not altered by dietary intervention or any of the treatment regimens (Fig. 5B,E). Interestingly, HbA1c was reduced (P<0.001) by all treatments when compared to saline HFF controls (Fig. 6C), and this benefit persisted (P<0.001) even after cessation of treatment (Fig. 6E). However, HbA1c of all HFF mice were elevated (P<0.001) when compared to lean controls (Fig. 6C,E).

3.6 Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on pancreatic islet architecture in HFF mice 
There were no obvious abnormalities in islet structure in any of the mice (Fig. 6A-E,I-M). At the end of the treatment period, islet and beta-cell areas were significantly (P<0.01 to P<0.001) increased in all HFF treatment groups compared to HFF controls, but decreased (P<0.05 to P<0.01) when compared to lean controls (Fig. 6F,G). Alpha-cell area was significantly reduced (P<0.001) by each treatment when compared to HFF controls, and similar to lean controls (Fig. 6H). Following cessation of treatment, islet and beta cell areas were significantly increased (P<0.05 – P<0.01) in the combined treatment group, and not different from lean control mice (Fig. 6N,O). HFF mice previously treated with exendin-4/gastrin also displayed similar benefits, but both islet and beta cell areas when reduced (P<0.05 and P<0.01; respectively) compared to lean controls (Fig. 6N,O). Similar to observations directly after the treatment period, alpha-cell area was significantly reduced (P<0.001) in all treatment groups, barring exendin-4/gastrin, when compared to HFF controls following 21 days cessation of treatment, and not different from lean control mice (Fig. 6P).  

4.	Discussion
In the present study, we have evaluated therapeutic interactions and overall preclinical antidiabetic efficacy following individual and combined treatment with exendin-4/gastrin (Dalboge et al. 2014) and xenin-8-Gln (Martin et al. 2016) in HFF mice. Previous studies have employed exendin-4/gastrin/xenin triple-acting hybrid peptides in a similar manner (Hasib et al. 2018b, 2019), but metabolic benefits were not as impressive as anticipated, possibly due to stearic hindrances related to lack of C-terminal amidation of gastrin (Stone et al. 2017). However, it should be noted that such amidation is not completely critical for the bioactivity of gastrin (Seva et al. 1994; Hollande et al. 1997). Thus, the triple-acting exendin-4/gastrin/xenin peptides still imparted some antidiabetic effects in various rodent models of T2DM (Hasib et al. 2018b, 2019). 
	Consistent with previous observations, the HFF mouse model on background low-dose STZ employed for the current study exhibited progressive body weight gain, increased energy intake, hyperglycaemia and impaired glucose tolerance when compared with age-matched lean control animals (Millar et al. 2016). Twice-daily treatment of these mice with exendin-4/gastrin or xenin-8-Gln reproduced the previously noted beneficial metabolic effects in T2DM (Hasib et al. 2018b). Thus, energy intake was reduced by both individual treatment regimens, and especially with exendin-4/gastrin, along with improvements in biochemical profiles, glucose tolerance, insulin sensitivity index and metabolic response to GIP, although only the exendin-4/gastrin intervention lowered body weight. This reduction of body weight is therefore a likely consequence of the enhanced satiety effect of exendin-4/gastrin, but pair-feeding studies would be required to confirm this. Thus, it should be noted that body weight reductions with exendin-4/gastrin could be partly related to improved metabolic profile in these mice. The main benefits of combined exendin-4/gastrin and xenin-8-Gln treatment were linked to augmented insulinotropic responses, with no impact on glucagon secretion. This is directly in keeping with integration of the individual benefits of GLP-1, gastrin and xenin signalling on overall pancreatic beta cell function (Xu et al. 1999; Rooman et al. 2002; Suarez-Pinzon et al. 2008; Khan et al. 2017). As such, circulating, glucose- and GIP-induced insulin concentrations were noticeably elevated in the combined treatment group.  
To further probe this concept, pancreatic architecture was evaluated in the HFF mice. Each of the treatments, namely xenin-8-Gln, exendin-4/gastrin or a combination of both peptides, increased beta cell area, but only combined treatment also increased overall pancreatic islet area. This is encouraging, given that the primary benefit of gastrin is most likely linked to augmentation of beta-cell mass (Fosgerau et al. 2013; Dalboge et al. 2014). Certainly, this is in keeping with the notion that C-terminal amidation of gastrin, although not completely essential for bioactivity (Seva et al. 1994; Hollande et al. 1997), may impart some benefit at the level of the pancreas (Hasib et al. 2018b, 2019). However, it should also be noted that potential improvements in insulin action and reduced overall insulin demand could impact upon current and previous observations with gastrin containing hybrid peptides (Buchanan et al. 2002). Indeed, pancreatic insulin content was elevated in all exendin-4/gastrin mice, with islet and beta-cell areas increased in the combination treatment group following  21-days cessation of treatment. Thus, the beneficial impact of gastrin on beta cell proliferation may be gradual in nature, as suggested previously (Dalboge et al. 2014), and persistent even in the face of treatment cessation. Distinct reductions in alpha cell area were noted with each treatment intervention, which were very persistent in nature in all HFF mice treated with xenin-8-Gln. This could be related to the impact of xenin-8 on glucagon secretion (Silvestre et al. 2013) and possible effects on alpha-cell proliferation/apoptosis, but further studies would be required to confirm this.  
Despite the notable positive effects of combined exendin-4/gastrin and xenin-8-Gln therapy, overall antidiabetic benefits were not remarkably better than exendin-4/gastrin alone. This might reflect a possible ceiling to the maximal metabolic benefit achievable thorough concurrent activation of GLP-1, gastrin and xenin cellular pathways in T2DM. Thus, peptide doses may need to be adjusted to allow enhancement over the advantages of each individual regimen. In addition, circulating glucose and glucose tolerance were essentially restored to normal levels by exendin-4/gastrin, likely precluding additive antidiabetic actions. However, in harmony with the positive interplay between xenin and GIP (Craig et al. 2018), addition of GIP receptor activation to therapy with exendin-4/gastrin/xenin-8-Gln was shown to substantially enhance pancreatic beta-cell mass in HFF mice (Hasib et al. 2018b). Notably, all four peptide entities are synthesised locally within islets and exert favourable beta-cell modulatory actions (Vasu et al. 2014; Khan et al. 2017, 2018). Such a multi-targeting approach could represent an interesting therapeutic angle for T2DM, with appropriate dose adjustment to ensure maximal additive metabolic benefits with minimal side-effects. 
An important observation in the current study was the persistence of beneficial effects following discontinuation of the respective treatment regimens. Indeed, pre-treatment with exendin-4/gastrin, xenin-8-Gln or a combination of both peptides was associated with reduced circulating glucose levels and improved insulin secretory responses. Importantly, body weights of all HFF mice were not significantly different at the end of the study, ruling out the possibility that advantages were simply a direct consequence of decreased body weight, which is well known to improve metabolic control (Magkos et al. 2016). The absence of compensatory increases in energy intake following treatment discontinuation would suggest sustainable metabolic benefits independent from energy regulation control. The mechanisms associated with the persistence of decreased energy intake could be related to positive reprogramming of energy flux or metabolic rate induced by the treatments. Notably, in mammals, the energy balance system shows much stronger opposition to weight loss than to weight gain (Hill et al. 2012) In keeping with this, body weight increased following treatment cessation in all groups of HFF mice, despite no obvious change in calorie intake, implying active treatment is required to provoke and maintain body weight reductions. Thus, it appears that energy balance may have taken some weeks to resynchronise following discontinuation of treatment regimens. Further studies are required to investigate this and the involvement of central pathways linked to energy regulation to decipher exact mechanisms. However, examining central pathways linked to energy regulation was not a primary objective of the current study, and we did not we collect brain tissue from the animals to investigate this further. Interestingly, the most prominent sustainable benefits were noted in the combination treatment group, with improvements in glucose and GIP tolerance still clearly observable even 21 days after the last peptide injection. This is undoubtedly associated with improved glucose handling, preservation of augmented pancreatic insulin concentrations and favourable long-term effects on pancreatic islet architecture, in particular beta-cell mass in these mice, as discussed above. Such sustainable pancreatic related benefits were not observed following treatment with xenin-8-Gln alone. Taken together, endurance of advantageous metabolic effects is a highly desirable feature given the progressive nature of T2DM (Kahn et al. 2006), as also seen with the thiazolidinedione class of drugs (Simard et al. 2015). 
             In conclusion, the present study reaffirms the antidiabetic benefits of modulation of GLP-1, gastrin and xenin cell signalling pathways. The pancreatic islet architectural improvements induced by combined exendin-4/gastrin and xenin-8-Gln administration do not appear to be associated with obvious metabolic benefits over exendin-4/gastrin/xenin-8-Gln (Hasib et al. 2018b), but may encourage enduring antidiabetic effects with obvious advantages for T2DM.
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Fig. 1. Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on (A) body weight, (B) fat mass, (C) cumulative energy intake, (D) non-fasting glucose and (E) insulin in HFF mice. Parameters were measured for 3 days prior to, 21 days during (indicated by horizontal black bar) and 21 days following cessation (indicated by horizontal open bar), of twice daily treatment with saline vehicle (0.9% (w/v) NaCl), exendin-4/gastrin, xenin-8-Gln or a combination of both peptides (all peptides at 25 nmol/kg bw). Values represent mean ± S.E.M. for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared to HFF saline controls. ∆P<0.05, ∆∆P<0.01 and ∆∆∆P<0.001 compared to lean controls.

Fig. 2. Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on glucose tolerance and insulin response to glucose in HFF mice. (A,B) Parameters were measured after twice daily treatment with saline vehicle (0.9% (w/v) NaCl), exendin-4/gastrin, xenin-8-Gln or a combination of both peptides (all peptides at 25 nmol/kg bw), or (C,D) following cessation of all treatments. (A-D) Glucose (18 mmol/kg body wt) was administered i.p. at t=0 min in non-fasted mice. Plasma glucose and insulin AUC values for 0–105 min post injection are shown in the insets. Values represent mean ± S.E.M. for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared to HFF saline controls. ∆P<0.05, ∆∆P<0.01, ∆∆∆P<0.001 compared to lean controls.

Fig. 3. Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on metabolic response to GIP in HFF mice. (A,B) Parameters were measured after twice daily treatment with saline vehicle (0.9% (w/v) NaCl), exendin-4/gastrin, xenin-8-Gln or a combination of both peptides (all peptides at 25 nmol/kg bw), or (C,D) following cessation of all treatments. (A-D) Glucose (18 mmol/kg bw) in combination with GIP (25 nmol/kg bw) was administered i.p. at t=0 min in non-fasted mice. Plasma glucose and insulin AUC values for 0–105 min post injection are shown in the insets. Values represent mean ± S.E.M. for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared to HFF saline controls. ∆P<0.05, ∆∆P<0.01, ∆∆∆P<0.001 compared to lean controls. ɸP<0.05, ɸɸP<0.01 compared to exendin-4/gastrin in combination with xenin-8-Gln.

Fig. 4. Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on insulin sensitivity in HFF mice. (A-C) Parameters were measured after twice daily treatment with saline vehicle (0.9% (w/v) NaCl), exendin-4/gastrin, xenin-8-Gln or a combination of both peptides (all peptides at 25 nmol/kg bw), or (D-F) following cessation of all treatments. (A,D) Insulin (20 U/kg bw) was administered i.p. at t=0 min in non-fasted mice. (B,E) Glucose AAC values for 0–105 min post insulin injection are also shown. (C,F) Insulin sensitivity index was calculated by the following equation: fasting glucose (mmol/L) x fasting insulin (mU/L). Values represent mean ± S.E.M. for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared to HFF saline controls. ∆P<0.05, ∆∆P<0.01, ∆∆∆P<0.001 compared to lean controls.

Fig. 5. Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on (A,D) pancreatic insulin content, (B,E) circulating glucagon and (C,F) %HbA1c in HFF mice. (A-C) Parameters were measured after twice daily treatment with saline vehicle (0.9% (w/v) NaCl), exendin-4/gastrin, xenin-8-Gln or a combination of both peptides (all peptides at 25 nmol/kg bw), or (D-F) following cessation of all treatments. Values represent mean ± S.E.M. for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared to HFF saline controls. ∆∆∆P<0.001 compared to lean controls.

Fig. 6. Effects of exendin-4/gastrin, xenin-8-Gln or a combination of both peptides on pancreatic islet architecture in HFF mice. (A-H) Parameters were measured after twice daily treatment with exendin-4/gastrin (25 nmol/kg bw), xenin-8-Gln (25 nmol/kg bw) or a combination of both peptides, or (I-P) following cessation of all treatments. (A-E and I-M) Representative images (20X) of islets showing insulin (red) and glucagon (green) immunoreactivity from each group of mice. (F,N) Islet, (G,O) beta and (H,P) alpha cell areas were measured using CellF image analysis software. Values are mean ± S.E.M. for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared to HFF saline controls. ∆P<0.05, ∆∆P<0.01, ∆∆∆P<0.001 compared to lean controls.
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